Detalhe da pesquisa
1.
SAR studies toward discovery of emvododstat (PTC299), a potent dihydroorotate dehydrogenase (DHODH) inhibitor.
Eur J Med Chem
; 244: 114826, 2022 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36242990
2.
Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia.
Front Oncol
; 12: 832816, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35223511
3.
BMI1 as a novel target for drug discovery in cancer.
J Cell Biochem
; 112(10): 2729-41, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21678481
4.
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent.
Mol Cancer Ther
; 20(10): 1846-1857, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34315764
5.
The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines.
Virus Res
; 292: 198246, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33249060
6.
The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines.
bioRxiv
; 2020 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32793904
7.
Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma.
Clin Cancer Res
; 25(18): 5548-5560, 2019 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31175095
8.
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
Mol Cancer Ther
; 18(1): 3-16, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30352802
9.
BMI1 is a therapeutic target in recurrent medulloblastoma.
Oncogene
; 38(10): 1702-1716, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30348991
10.
Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.
Oncotarget
; 9(47): 28547-28560, 2018 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29983879
11.
Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer.
Mol Cancer Ther
; 17(1): 39-49, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29158468
12.
Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer.
Mol Cancer Ther
; 17(10): 2136-2143, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30026381
13.
Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein Translation.
Clin Pharmacol Drug Dev
; 5(4): 296-305, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27310330
14.
BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer.
Clin Cancer Res
; 22(24): 6176-6191, 2016 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27307599
15.
Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform.
PLoS One
; 11(12): e0168366, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27992500
16.
Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression.
Sci Transl Med
; 8(350): 350ra104, 2016 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27488898
17.
Self-renewal as a therapeutic target in human colorectal cancer.
Nat Med
; 20(1): 29-36, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24292392